Fresenius Medical Care (NYSE:FMS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Saturday morning. The brokerage issued a strong-buy rating on the stock.

Separately, Truist Financial decreased their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Hold and an average price target of $22.00.

Fresenius Medical Care Stock Down 0.2 %

NYSE FMS opened at $20.88 on Friday. The stock has a fifty day moving average of $19.51 and a 200-day moving average of $19.91. The stock has a market capitalization of $12.25 billion, a P/E ratio of 23.46, a price-to-earnings-growth ratio of 1.09 and a beta of 0.90. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $23.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. On average, equities research analysts forecast that Fresenius Medical Care will post 1.51 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after purchasing an additional 758 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Fresenius Medical Care by 19.5% in the first quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock valued at $1,048,000 after purchasing an additional 8,870 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Fresenius Medical Care by 50.0% in the first quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock valued at $294,000 after purchasing an additional 5,078 shares in the last quarter. Wulff Hansen & CO. lifted its holdings in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC bought a new stake in shares of Fresenius Medical Care in the first quarter valued at about $584,000. 8.25% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.